CCM
ARQT icon

CAAS Capital Management’s Arcutis Biotherapeutics ARQT Stock Holding History

CAAS Capital Management’s Portfolio ARQT Stock Details ARQT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q2 		– Sell
-22,413
Closed -$668K – 410
2020
Q1 		$668K Buy
+22,413
New +$602K 0.07% 157

Other funds holding ARQT

FM
Frazier Management Seattle, Washington $1.12M AUM 151.58% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
OFM
Omega Fund Management Boston, Massachusetts $163M AUM 107.06% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

CAAS Capital Management's ARQT Position: Q2 2020 in Review

CAAS Capital Management sold out of Arcutis Biotherapeutics (ARQT) in Q2 2020, closing a stake of 22,413 shares — an estimated $668K sold.

CAAS Capital Management first reported a position in ARQT in Q1 2020 and held it in 1 quarter. The position peaked at $668K in Q1 2020. 56 funds tracked by Wall St. Rank hold ARQT as of Q2 2020.

  • CAAS Capital Management reported no remaining Arcutis Biotherapeutics position as of Q2 2020 after selling out during the quarter.
  • CAAS Capital Management sold 22,413 Arcutis Biotherapeutics shares in Q2 2020, an estimated $668K.
  • CAAS Capital Management first reported a position in Arcutis Biotherapeutics in Q1 2020 and held it in 1 quarter.
  • CAAS Capital Management's Arcutis Biotherapeutics position peaked at $668K in Q1 2020.
  • 56 funds tracked by Wall St. Rank held Arcutis Biotherapeutics as of Q2 2020.

Based on CAAS Capital Management's 13F filing for Q2 2020, filed 14 Aug 2020.